Clinical Trials Logo

Central Precocious Puberty clinical trials

View clinical trials related to Central Precocious Puberty.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05029622 Completed - Clinical trials for Central Precocious Puberty

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

Start date: August 10, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the protocol is to assess the efficacy of the triptorelin 6 month PR (Prolonged Release) formulation in suppressing LH (Luteinising hormone) levels to prepubertal levels (defined as a peak LH ≤5 IU/L) after i.v. GnRH (Gonadotropin-releasing Hormone) stimulation at Month 6 (Day 169) in Chinese children with CPP (Central Precocious Puberty).

NCT ID: NCT04736602 Completed - Clinical trials for Central Precocious Puberty

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

Start date: March 27, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to observe whether the Triptorelin pamoate 15mg (3-month formulation) effectiveness in Chinese population of CPP children has the same or similar trend with that in overseas CPP population. This is measured by assessing the proportion of children who have a suppressed Luteinizing Hormone (LH) response to Gonadotropin Releasing Hormone (GnRH) test performed 3 months after injection of triptorelin.

NCT ID: NCT03316482 Completed - Clinical trials for Central Precocious Puberty

Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty

Start date: June 11, 2015
Phase: Phase 4
Study type: Interventional

A multicenter, open-label, prospective study to evaluate the safety and efficacy of leuprorelin acetate DPS (Leuplin DPS) treatment quarterly in patients with central precocious puberty

NCT ID: NCT02993926 Completed - Clinical trials for Central Precocious Puberty

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Start date: June 24, 2017
Phase:
Study type: Observational

The purpose of this study is to evaluate the long-term safety and efficacy of Enantone in the treatment of CPP in Chinese participants.

NCT ID: NCT02920515 Completed - Clinical trials for Central Precocious Puberty

Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty

Start date: September 2012
Phase: Phase 4
Study type: Interventional

This is a prospective, multicentric, comparative, non-randomized interventional study in which subjects diagnosed with central precocious puberty (CPP) and early puberty (EP) were treated for 6 months to compare the effect with GnRHa and traditional Chinese medicines.

NCT ID: NCT02427958 Completed - Clinical trials for Central Precocious Puberty

A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants

Start date: August 7, 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess long-term safety and efficacy of leuprorelin in the treatment of Central Precocious Puberty (CPP).

NCT ID: NCT01634321 Completed - Clinical trials for Central Precocious Puberty

The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty

Start date: July 2011
Phase: Phase 4
Study type: Interventional

The purpose of this Clinical Trial was to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide acetate 3.75mg) in patients with precocious puberty.

NCT ID: NCT01467882 Completed - Clinical trials for Central Precocious Puberty

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Start date: April 2012
Phase: Phase 3
Study type: Interventional

The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).

NCT ID: NCT01278290 Completed - Clinical trials for Central Precocious Puberty

Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The aim of the study is to determine the specificity, sensitivity and diagnostic efficiency of the Triptorelin Test in the assessment of CPP compared to GnRH test as gold standard. Hypothesis: Aqueous Triptorelin Acetate is so efficient as GnRH to CPP assessment. Study population are girls with suspicious clinical features of precocious puberty

NCT ID: NCT00779103 Completed - Clinical trials for Central Precocious Puberty

Histrelin Subcutaneous Implant in Children With Central Precocious Puberty

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to follow and collect additional medical and developmental information on children after histrelin subcutaneous implant therapy is discontinued.